Please login to the form below

Not currently logged in
Email:
Password:

Sun gets FDA marketing nod for Protonix

Sun Pharmaceutical wins FDA approval for its ANDA to market a generic version of Wyeth's Protonix tablets

India-headquartered generic manufacturer Sun Pharmaceutical has won FDA approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Wyeth's Protonix tablets (pantoprazole).

Pantoprazole is indicated for the short-term treatment of erosive esophagitis associated with GERD, maintenance of healing of erosive esophagitis and for the treatment of hypersecretory diseases.

Sun's generic pantoprazole tablets are copies of Wyeth's Protonix Delayed Release Tablets and include 20 mg and 40 mg doses, both of which post annual US sales of around USD 2.3bn.

Sun, which was the first-to-file its generic Protonix ANDA with a Paragraph IV certification, also gains a 180-day marketing exclusivity.

Sun stated that it was now mulling its launch options.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics